Categories: HealthcareNews

AcuityMD Secures $45M in Series B Funding to Expand its Commercial Intelligence Platform to Medical Technology Manufacturers

BOSTON–(BUSINESS WIRE)–AcuityMD today announced $45 million in new funding to expand its commercial intelligence platform and advance the company’s mission of accelerating adoption of cutting-edge medical technology (MedTech). The Series B round was led by ICONIQ Growth, with additional participation from Boston-based Atreides Management and New York-based Stepstone Group as well as existing investors Redpoint Ventures, Benchmark Capital, and Artisanal Ventures. To date, AcuityMD has raised more than $83 million and achieved a significant 10x increase in annual recurring revenue since its 2022 Series A raise.


ICONIQ Growth has been the leading investor in the Forbes Cloud 100 since its inception, investing in companies such as Snowflake, Datadog, and GitLab, as well as leading vertical software companies including Procore, ServiceTitan, Benchling, QGenda, and Komodo Health. The company also has a healthcare advisory council that includes top executives from Johnson & Johnson, Stanford Healthcare, and Cleveland Clinic.

“AcuityMD is a market leader in commercial MedTech software with powerful data and prospecting insights that have elicited positive feedback from customers,” said Tengbo Li, Partner at ICONIQ Growth. “AcuityMD’s innovative platform is reminiscent of other transformative, vertical-specific platforms that we have supported. We believe that there are also exciting opportunities to extend into other product areas and expand the value proposition, and ultimately for MedTech companies to use AcuityMD as their complete commercial operating system.”

Notably, four AcuityMD investors are former MedTech CEOs, including Bill Hawkins, former CEO of Medtronic. “I’m acutely aware of the unique challenges MedTech companies face when bringing products to market,” said Hawkins. “AcuityMD has built an industry-specific platform that alleviates common pain points to help bring new treatments to patients faster. I am thrilled to be partnering with AcuityMD as it enters its next phase of growth.”

Since its founding in 2019, AcuityMD has experienced rapid growth, now supporting more than 200 MedTech manufacturers – including six of the top 10 – with its commercial intelligence platform. AcuityMD is also ranked in the top quartile of B2B software companies in customer retention and growth based on analysis from ICONIQ Growth’s “Topline Growth & Operational Efficiency” study.

AcuityMD’s commercial platform translates large volumes of healthcare data, such as physician procedural volumes, product preferences, sites of care affiliations, peer networks, and referral patterns into intuitive workflows and recommendations that align with the MedTech industry’s unique commercial process. It has resulted in more than 25% sales growth for top active sales reps and over $10 billion in opportunity pipeline created.

“We are fortunate to work with fantastic financial partners as well as experienced MedTech industry executives who broaden the perspective of our Customer Advisory Board,” said Michael Monovoukas, CEO and co-founder of AcuityMD. “With this additional capital, we aim to launch three new products to general availability, expand our pipeline management solution to more customers, and grow our engineering and product teams by 70% by the end of 2024 to support our mission of accelerating the adoption of cutting-edge medical technology.”

AcuityMD continues to grow even in a cooling market, where Series B deal sizes peaked in 2021 with $46M, followed by a steep decline that hit its lowest point of $30M average in Q4 2023. The average investment is slowly increasing again, with an average of $38.9M in January 2024 – still $5 million less than AcuityMD’s latest raise.

In other news today, AcuityMD announced that its platform is being leveraged by six of the top 10 global MedTech companies, including BD (Becton, Dickinson and Company).

About ICONIQ Growth

ICONIQ Growth partners with visionaries defining the future of their industries to transform the world. Our investment platform and unique ecosystem helps amplify our portfolio companies’ success from early growth stage to IPO and beyond. Our portfolio includes Adyen, AirBnB, Alibaba, Alteryx, Automattic, BambooHR, Braze, Chime, Collibra, Coupa, Datadog, Docusign, Gitlab, Marqeta, Miro, Procore, Red Ventures, Relativity, ServiceTitan, Snowflake, Sprinklr, Truckstop, Uber, Wolt, and Zoom, among others. For more information, please visit ICONIQGrowth.com.

About AcuityMD

AcuityMD is a leading technology partner to the commercial MedTech industry. Over 200 companies use AcuityMD’s commercial platform to identify target markets, surface top opportunities, and grow their business. With customers ranging from pre-commercial to enterprise, AcuityMD is committed to providing MedTech companies with unparalleled visibility to accelerate adoption of cutting-edge medical technology. For more information, visit acuitymd.com.

Contacts

Media:
Lisa Barbadora, BarbadoraINK for AcuityMD

+1 (610) 420-3413

lbarbadora@barbadoraink.com

Staff

Recent Posts

AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

20 hours ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

20 hours ago

Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

20 hours ago

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles

Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…

20 hours ago

Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger

CRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or…

20 hours ago

Park Dental Partners Announces Dates for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK), a leading…

20 hours ago